增加L-SIGN特异性糖模拟物的化学空间

IF 6.8 1区 医学 Q1 CHEMISTRY, MEDICINAL
Gianluca Cavazzoli, Clara Delaunay, Sara Pollastri, Andrea Panzeri, Sara Sattin, Michel Thépaut, Laura Belvisi, Franck Fieschi, Anna Bernardi
{"title":"增加L-SIGN特异性糖模拟物的化学空间","authors":"Gianluca Cavazzoli, Clara Delaunay, Sara Pollastri, Andrea Panzeri, Sara Sattin, Michel Thépaut, Laura Belvisi, Franck Fieschi, Anna Bernardi","doi":"10.1021/acs.jmedchem.5c01448","DOIUrl":null,"url":null,"abstract":"Selective ligands for the C-type lectin receptor L-SIGN offer promising avenues in antiviral therapies and for tissue-specific delivery. We recently reported that a guanidine-bearing modified mannose glycomimetic, called <b>Man84</b>, binds to L-SIGN with micromolar affinity and high-selectivity against the homologue lectin DC-SIGN. Here we describe a series of <b>Man84</b> isosteres (ligands <b>2–11</b>) that maintain or improve on this selectivity. The affinity of the ligands for L-SIGN, as well as their selectivity against DC-SIGN, were evaluated by Surface Plasmon Resonance inhibition assays using immobilized SARS-CoV-2 Spike protein. Compounds <b>4</b>, <b>5</b> and <b>9</b> were found to bind to L-SIGN with low micromolar affinity and 50–94-fold selectivity, thus matching or exceeding the performance of <b>Man84</b>. The crystal structure of the L-SIGN CRD/<b>4</b> complex was solved and highlighted the critical role of a bidentate H-bond interaction of the ligands with the side chain of E370 in L-SIGN.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"1 1","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2025-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Increasing the Chemical Space of L-SIGN Specific Glycomimetics\",\"authors\":\"Gianluca Cavazzoli, Clara Delaunay, Sara Pollastri, Andrea Panzeri, Sara Sattin, Michel Thépaut, Laura Belvisi, Franck Fieschi, Anna Bernardi\",\"doi\":\"10.1021/acs.jmedchem.5c01448\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Selective ligands for the C-type lectin receptor L-SIGN offer promising avenues in antiviral therapies and for tissue-specific delivery. We recently reported that a guanidine-bearing modified mannose glycomimetic, called <b>Man84</b>, binds to L-SIGN with micromolar affinity and high-selectivity against the homologue lectin DC-SIGN. Here we describe a series of <b>Man84</b> isosteres (ligands <b>2–11</b>) that maintain or improve on this selectivity. The affinity of the ligands for L-SIGN, as well as their selectivity against DC-SIGN, were evaluated by Surface Plasmon Resonance inhibition assays using immobilized SARS-CoV-2 Spike protein. Compounds <b>4</b>, <b>5</b> and <b>9</b> were found to bind to L-SIGN with low micromolar affinity and 50–94-fold selectivity, thus matching or exceeding the performance of <b>Man84</b>. The crystal structure of the L-SIGN CRD/<b>4</b> complex was solved and highlighted the critical role of a bidentate H-bond interaction of the ligands with the side chain of E370 in L-SIGN.\",\"PeriodicalId\":46,\"journal\":{\"name\":\"Journal of Medicinal Chemistry\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":6.8000,\"publicationDate\":\"2025-10-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medicinal Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1021/acs.jmedchem.5c01448\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.jmedchem.5c01448","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

摘要

c型凝集素受体L-SIGN的选择性配体为抗病毒治疗和组织特异性递送提供了有希望的途径。我们最近报道了一种含有胍的修饰甘露糖拟糖物Man84,它以微摩尔亲和力和高选择性结合L-SIGN,对抗同系物凝集素DC-SIGN。在这里,我们描述了一系列保持或提高这种选择性的Man84同位体(配体2-11)。利用固定的SARS-CoV-2刺突蛋白,通过表面等离子体共振抑制实验评估了配体对L-SIGN的亲和力以及对DC-SIGN的选择性。化合物4、5和9与L-SIGN的结合具有低的微摩尔亲和力和50 - 94倍的选择性,从而达到或超过了Man84的性能。对L-SIGN CRD/4配合物的晶体结构进行了解析,并强调了配体与L-SIGN中E370侧链的双齿h键相互作用的关键作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Increasing the Chemical Space of L-SIGN Specific Glycomimetics

Increasing the Chemical Space of L-SIGN Specific Glycomimetics
Selective ligands for the C-type lectin receptor L-SIGN offer promising avenues in antiviral therapies and for tissue-specific delivery. We recently reported that a guanidine-bearing modified mannose glycomimetic, called Man84, binds to L-SIGN with micromolar affinity and high-selectivity against the homologue lectin DC-SIGN. Here we describe a series of Man84 isosteres (ligands 2–11) that maintain or improve on this selectivity. The affinity of the ligands for L-SIGN, as well as their selectivity against DC-SIGN, were evaluated by Surface Plasmon Resonance inhibition assays using immobilized SARS-CoV-2 Spike protein. Compounds 4, 5 and 9 were found to bind to L-SIGN with low micromolar affinity and 50–94-fold selectivity, thus matching or exceeding the performance of Man84. The crystal structure of the L-SIGN CRD/4 complex was solved and highlighted the critical role of a bidentate H-bond interaction of the ligands with the side chain of E370 in L-SIGN.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Medicinal Chemistry
Journal of Medicinal Chemistry 医学-医药化学
CiteScore
4.00
自引率
11.00%
发文量
804
审稿时长
1.9 months
期刊介绍: The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents. The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信